Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17355823 | 0.93 | MRGPRX4 (0.50) | MRGPRX4HTTMAPTALDH1A1PTGDR2 | |
| SCHEMBL17355736 | 0.82 | NR1H4 (0.49) | MRGPRX4HTTMAPTALDH1A1PTGDR2 | |
| SCHEMBL17355771 | 0.80 | MRGPRX4 (0.52) | MRGPRX4HTTMAPTALDH1A1PTGDR2 | |
| SCHEMBL17355807 | 0.79 | MRGPRX4 (0.50) | MRGPRX4HTTMAPTPTGDR2POLQ | |
| SCHEMBL17355820 | 0.76 | MRGPRX4 (0.49) | MRGPRX4 | |
| SCHEMBL17355853 | 0.76 | MRGPRX4 (0.42) | MRGPRX4HTTALDH1A1PTGDR2POLQ | |
| SCHEMBL17355803 | 0.75 | MRGPRX4 (0.51) | MRGPRX4HTTMAPTALDH1A1PTGDR2 | |
| SCHEMBL17355656 | 0.75 | PPARG (0.47) | HTTMAPTALDH1A1RAB9AGAA | |
| SCHEMBL17355829 | 0.75 | KMT2A (0.49) | MRGPRX4HTTMAPTPTGDR2POLQ | |
| SCHEMBL17355664 | 0.73 | MAPT (0.42) | HTTMAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | HCN2, SCO2, HCN1 | MRGPRX4 4355/4885HTT 4399/4885MAPT 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.